Amgen has announced it is developing its already marketed psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the SARS-CoV-2 coronavirus.
Bristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion takeover of Celgene through the financial regulatory seas.